Glenn L Cooper MD
First SEC filing: Sept. 13, 2011 · Latest: Sept. 13, 2011
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| May 23, 2019 | RGEN | M | 24,000 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-06) |
| May 23, 2019 | RGEN | S | 266 | $67.53 | $17,963 | 59,709 Direct | -0.44% | Disposed | 158.9% (price as of 2026-10-06) |
| May 23, 2019 | RGEN | S | 4,734 | $66.91 | $316,752 | 59,975 Direct | -7.32% | Disposed | 161.3% (price as of 2026-10-06) |
| May 23, 2019 | RGEN | M | 24,000 | $5.00 | $120,000 | 64,709 Direct | +58.96% | Acquired | 3397.2% (price as of 2026-10-06) |
| May 23, 2019 | RGEN | S | 266 | $67.53 | $17,963 | 35,709 Direct | -0.74% | Disposed | 158.9% (price as of 2026-10-06) |
| May 23, 2019 | RGEN | S | 4,734 | $66.91 | $316,752 | 35,975 Direct | -11.63% | Disposed | 161.3% (price as of 2026-10-06) |
| May 15, 2019 | RGEN | A | 2,109 | · | · | 2,109 Direct | · | Acquired | (price as of 2026-10-06) |
| May 15, 2019 | RGEN | A | 923 | · | · | 40,709 Direct | +2.32% | Acquired | (price as of 2026-10-06) |
| May 16, 2018 | RGEN | A | 3,304 | · | · | 3,304 Direct | · | Acquired | (price as of 2026-10-06) |
| May 16, 2018 | RGEN | A | 1,486 | · | · | 39,786 Direct | +3.88% | Acquired | (price as of 2026-10-06) |
| May 18, 2017 | RGEN | A | 2,434 | · | · | 2,434 Direct | · | Acquired | (price as of 2026-10-06) |
| May 18, 2017 | RGEN | A | 1,206 | · | · | 38,300 Direct | +3.25% | Acquired | (price as of 2026-10-06) |
| May 11, 2016 | RGEN | A | 3,366 | · | · | 3,366 Direct | · | Acquired | (price as of 2026-10-06) |
| May 11, 2016 | RGEN | A | 1,763 | · | · | 37,094 Direct | +4.99% | Acquired | (price as of 2026-10-06) |
| Nov. 9, 2015 | RGEN | A | 1,000 | $26.56 | $26,560 | 35,331 Direct | +2.91% | Acquired | 558.4% (price as of 2026-10-06) |
| May 21, 2015 | RGEN | A | 1,992 | · | · | 1,992 Direct | · | Acquired | (price as of 2026-10-06) |
| May 21, 2015 | RGEN | A | 1,019 | · | · | 34,331 Direct | +3.06% | Acquired | (price as of 2026-10-06) |
| May 15, 2014 | RGEN | A | 3,696 | · | · | 3,696 Direct | · | Acquired | (price as of 2026-10-06) |
| May 15, 2014 | RGEN | A | 1,932 | · | · | 33,312 Direct | +6.16% | Acquired | (price as of 2026-10-06) |
| May 9, 2013 | RGEN | A | 5,342 | · | · | 31,380 Direct | +20.52% | Acquired | (price as of 2026-10-06) |
| Nov. 30, 2012 | FBIOP | P | 3,811 | $4.02 | $15,320 | 43,811 Direct | +9.53% | Acquired | 362.2% (price as of 2026-10-06) |
| Sept. 21, 2012 | RGEN | P | 3,000 | $6.09 | $18,270 | 24,038 Direct | +14.26% | Acquired | 2771.3% (price as of 2026-10-06) |
| Sept. 21, 2012 | RGEN | P | 2,000 | $6.08 | $12,160 | 26,038 Direct | +8.32% | Acquired | 2776.0% (price as of 2026-10-06) |
| Sept. 21, 2012 | RGEN | P | 5,000 | $6.09 | $30,450 | 21,038 Direct | +31.18% | Acquired | 2771.3% (price as of 2026-10-06) |
| June 22, 2012 | FBIOP | P | 10,000 | $5.30 | $53,000 | 40,000 Direct | +33.33% | Acquired | 250.6% (price as of 2026-10-06) |
| May 24, 2012 | RGEN | A | 11,038 | · | · | 16,038 Direct | +220.76% | Acquired | (price as of 2026-10-06) |
| Feb. 10, 2012 | FBIOP | A | 45,000 | · | · | 45,000 Direct | · | Acquired | (price as of 2026-10-06) |
| Dec. 15, 2011 | RGEN | A | 15,000 | · | · | 59,000 Direct | +34.09% | Acquired | (price as of 2026-10-06) |
| Sept. 16, 2010 | RGEN | A | 20,000 | · | · | 44,000 Direct | +83.33% | Acquired | (price as of 2026-10-06) |
| Nov. 9, 2009 | RGEN | P | 5,000 | $4.98 | $24,900 | 5,000 Direct | · | Acquired | 3411.2% (price as of 2026-10-06) |
| Aug. 24, 2009 | RGEN | A | 24,000 | · | · | 24,000 Direct | · | Acquired | (price as of 2026-10-06) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| May 23, 2019 | RGEN | Stock Option (Right to Buy) | Common Stock | $5.00 | Aug. 24, 2019 | 24,000 | Disposed |
| May 15, 2019 | RGEN | Stock Option (Right to Buy) | Common Stock | $67.71 | May 15, 2029 | 2,109 | Acquired |
| May 16, 2018 | RGEN | Stock Option (Right to Buy) | Common Stock | $42.07 | May 16, 2028 | 3,304 | Acquired |
| May 18, 2017 | RGEN | Stock Option (Right to Buy) | Common Stock | $38.76 | May 18, 2027 | 2,434 | Acquired |
| May 11, 2016 | RGEN | Stock Option (Right to Buy) | Common Stock | $26.12 | May 11, 2026 | 3,366 | Acquired |
| May 21, 2015 | RGEN | Stock Option (Right to Buy) | Common Stock | $41.19 | May 21, 2025 | 1,992 | Acquired |
| May 15, 2014 | RGEN | Stock Option (Right to Buy) | Common Stock | $18.12 | May 15, 2024 | 3,696 | Acquired |
| Feb. 10, 2012 | FBIOP | Options to purchase Common Stock | Common Stock | $6.25 | Feb. 10, 2022 | 45,000 | Acquired |
| Dec. 15, 2011 | RGEN | Stock Option (Right to Buy) | Common Stock | $3.22 | Dec. 15, 2021 | 15,000 | Acquired |
| Sept. 16, 2010 | RGEN | Stock Option (Right to Buy) | Common Stock | $3.30 | Sept. 16, 2020 | 20,000 | Acquired |
| Aug. 24, 2009 | RGEN | Stock Option (Right to Buy) | Common Stock | $5.00 | Aug. 24, 2019 | 24,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2011 | $225,000 | · | · | · | · | · | $97,500 | $322,500 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.